Gilead Sciences Inc (GILD)

Mar 30, 2025, 8:00 AM EDT - 1 day ago

Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)

AMAT APH BK BMY CTAS EOG EQH

Mar 27, 2025, 10:22 AM EDT - 4 days ago

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

ABBV AMGN BIIB BMY IHE JNJ LLY

Mar 23, 2025, 12:36 PM EDT - 8 days ago

Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval

Mar 19, 2025, 9:22 AM EDT - 12 days ago

Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding

Mar 14, 2025, 1:51 PM EDT - 17 days ago

Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly

LLY SBUX SHAK MMM

Mar 12, 2025, 8:30 AM EDT - 19 days ago

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

Mar 11, 2025, 2:14 PM EDT - 20 days ago

Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)

Mar 11, 2025, 1:40 PM EDT - 20 days ago

Stocks beating the stock market's recent Trump slump have this in common

ABBV AMGN BAX CVS PM SMCI TPL

Mar 11, 2025, 1:37 PM EDT - 20 days ago

First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

Mar 5, 2025, 1:31 PM EST - 26 days ago

5 Big Biopharmaceutical Stocks That Are Finding Favor

ABBV AMGN JNJ LLY

Mar 4, 2025, 2:04 PM EST - 27 days ago

Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)

Mar 4, 2025, 7:03 AM EST - 27 days ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT PRVA TGTX TKO

Mar 3, 2025, 11:21 AM EST - 4 weeks ago

Gilead Sciences sets aside $200 million to resolve HIV drug probe

Feb 26, 2025, 10:55 PM EST - 4 weeks ago

Why Gilead Sciences Remains A Buy After A 40% Rally

Feb 25, 2025, 8:00 AM EST - 4 weeks ago

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer

Feb 24, 2025, 8:30 AM EST - 5 weeks ago

European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Feb 20, 2025, 4:30 PM EST - 5 weeks ago

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Feb 19, 2025, 4:05 PM EST - 5 weeks ago

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 18, 2025, 12:59 PM EST - 5 weeks ago

Calls of the Day: Gilead Sciences and Merck

MRK

Feb 18, 2025, 8:30 AM EST - 5 weeks ago

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Feb 14, 2025, 1:31 PM EST - 6 weeks ago

Josh Brown's best stocks

CTVA UNP

Feb 12, 2025, 3:22 PM EST - 6 weeks ago

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Feb 12, 2025, 8:25 AM EST - 6 weeks ago

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

Feb 11, 2025, 8:40 PM EST - 6 weeks ago

Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:08 PM EST - 6 weeks ago

Gilead quarterly results beat estimates

Feb 11, 2025, 4:05 PM EST - 6 weeks ago

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

Feb 11, 2025, 4:02 PM EST - 6 weeks ago

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 3:04 AM EST - 6 weeks ago

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Feb 7, 2025, 12:56 PM EST - 7 weeks ago

KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited

Feb 5, 2025, 6:32 PM EST - 7 weeks ago

Final Trade: UBER, MP, MGNI, GILD

UBER MGNI MP

Feb 3, 2025, 4:56 PM EST - 2 months ago

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 3, 2025, 10:36 AM EST - 2 months ago

Trump gives a lift to healthcare stocks with comments on Medicare and Medicaid

ABBV CNC ELV HCA MOH

Jan 31, 2025, 3:31 PM EST - 2 months ago

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

BMY MRK

Jan 30, 2025, 8:00 AM EST - 2 months ago

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

CTSH

Jan 28, 2025, 4:05 PM EST - 2 months ago

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 15, 2025, 3:45 PM EST - 2 months ago

Gilead Sciences, US government settle patent case over HIV prevention drugs

Jan 13, 2025, 6:32 PM EST - 2 months ago

Final Trade: ANF, GILD

ANF

Jan 13, 2025, 6:10 PM EST - 2 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GSK IBB

Jan 13, 2025, 5:09 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Jan 13, 2025, 11:15 AM EST - 2 months ago

Gilead CEO on funding for new HIV prevention medicine

Jan 13, 2025, 11:11 AM EST - 2 months ago

Gilead's new HIV prevention drug lenacapavir will ‘change the face of HIV,' says CEO Daniel O'Day

Jan 13, 2025, 9:01 AM EST - 2 months ago

Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV

Jan 11, 2025, 12:40 PM EST - 2 months ago

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Jan 11, 2025, 11:00 AM EST - 2 months ago

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Dec 29, 2024, 3:51 AM EST - 3 months ago

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 20, 2024, 4:05 PM EST - 3 months ago

Gilead Sciences to Present at Upcoming Investor Conference

Dec 18, 2024, 1:53 AM EST - 3 months ago

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 17, 2024, 8:30 AM EST - 3 months ago

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Dec 17, 2024, 7:00 AM EST - 3 months ago

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

Dec 13, 2024, 6:37 AM EST - 3 months ago

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis